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Pseudoprogression during successful rechallenge of immune 
checkpoint inhibitor in a NSCLC patient
Abstract
Rechallenge of immune checkpoint inhibitors (ICPIs) is one of the attractive but unestablished treatment for recurrent non-small 
cell lung cancer (NSCLC) patients who have been treated with several lines of systemic chemotherapy. In some NSCLC patients, 
the effects of ICPI rechallenge therapy have become apparent. In ICPI treatment, although very rare, a phenomenon called 
pseudoprogression is known. We report the first case of pseudoprogression during successful rechallenge of ICPI in a NSCLC 
patient. Although not fully clarified, factors related to the onset of pseudoprogression and good response to ICPI rechallenge are 
being investigated. Our case showed that pseudoprogression could be developed even in patients with ICPI rechallenge therapy. 
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Introduction
With the development of immune checkpoint 
inhibitors (ICPIs), treatment of advanced non-
small cell lung cancer (NSCLC) has dramatically 
changed [1]. At present, ICPIs are available in 
first-line NSCLC treatment with or without che-
motherapy, and they can be administered even 
after the second or later line treatments. This clin-
ical situation may provide opportunities for ICPI 
rechallenge therapy in later lines after the recur-
rence on post-ICPI chemotherapy or driver gene 
targeted therapies. In some NSCLC patients, the 
effects of ICPI rechallenge therapy have become 
apparent [2–7]. We have encountered a NSCLC 
patient who showed pseudoprogression [8–11], 
which is very rare phenomenon in this therapy, 
during successful ICPI rechallenge treatment. 
To our best knowledge, this is the first case with 
such a very rare phenomenon during successful 
rechallenge of ICPI therapy.
Case report
A 68-year-old man presented with abnormal 
opacity on chest radiograph detected incidentally. 
The patient underwent a whole-body computed 
tomography (CT) , which revealed a nodule in the 
middle lobe and multiple small nodules in both 
lung. He was pathologically diagnosed to have 
adenocarcinoma of the lung. On immunohisto-
chemical staining for programmed death-ligand 
1 (PD-L1) using the PD-L1 IHC 22C3 (pharmDX 
Dako, Merck & Co, NJ, USA), 75% of the tumor 
cells were positively stained. No driver gene was 
found. He received first-line chemotherapy with 
carboplatin and pemetrexed. As therapeutic effect 
was evaluated as stable disease (SD), he received 
additional 12 courses of maintenance therapy with 
pemetrexed. Despite of the treatment, regrowth in 
left mediastinal lymph nodes was detected in CT 
scan. Therefore, the patient received an immune 
checkpoint inhibitor (ICPI), pembrolizumab as 
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second-line therapy, considering high PD-L1 re-
sults. Seven months after the initiation of pem-
brolizumab, recurrence on left mediastinal lesion 
was found again in CT scan. Then the patient 
received the third- and fourth-line chemotherapy 
with docetaxel and ramucirumab, and carbopla-
tin, pemetrexed and bevacizumab. Response of 
third- and fourth-line therapy was evaluated as 
SD. Ten months after the initiation of the fourth-
line chemotherapy, regrowth of left mediastinal 
lesion and development of multiple small lung 
metastases in both lungs (Figure 1A) were ob-
served. The development of spinal metastases was 
also found in CT scan. After fully explaining and 
confirming the patient’s consent, ICPI rechallenge 
using nivolumab was initiated. Simultaneously, 
irradiation to the vertebral metastatic lesion was 
performed. In chest CT scan taken at 4 weeks after 
the initiation of the rechallenge therapy, the left 
mediastinal lesion was enlarged and the increase 
in size of pulmonary metastases were found (Fig-
ure 1B). However, the patient’s general condition 
did not deteriorate and his willingness to treat was 
strong, so treatment was continued. In chest CT 
scan taken at 12 weeks after the initiation of the 
rechallenge therapy, the left mediastinal lesion 
was shrunk and pulmonary metastases decreased 
in size or disappeared (Figure 1C). Response 
was evaluated as PR. Thereafter, nivolumab was 
continued for 3 months and he was well with 
no recurrence. In chemotherapies, the patient 
developed G3 neutropenia, but had no thrombo-
cytopenia. There was no development of febrile 
neutropenia. In ICPI therapies, the patient had no 
immune-related adverse event. The consecutive 
lines of treatment in the man with progression-free 
survival indication is shown in Figure 2.
Discussion
At present, according to some guidelines, in 
patients with high PD-L1 expression (> 50%), 
pembrolizumab in the first-line setting is recom-
mended (ESMO and NCCN) [12, 13]. However, 
first-line treatment in our patient started 3 months 
before pembrolizumab became available in our 
country. Therefore, the first-line treatment was 
chemotherapy instead of pembrolizumab.
Figure 1. Regrowth of the left mediastinal lesion was found in chest CT scan 10 months after the initiation of the fourth-line chemotherapy (A). 
Enlargement of the left mediastinal lesion and pulmonary metastases were found in chest CT scan taken at 4 weeks after the initiation of the re-
challenge therapy (B). The left mediastinal lesion was shrunk and pulmonary metastases decreased in size or disappeared in chest CT scan taken 
at 12 weeks after the initiation of the rechallenge therapy (C)
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Pseudoprogression has been defined as an 
initial disease progression followed by a subse-
quent response [8]. This phenomenon is rare, 
and it is reported in 2% to 8% of patients with 
advanced NSCLC treated with anti-PD-1/PD-
L1 agents [9–11]. Pseudoprogression was only 
observed in patients who received ICPC therapy 
for the first time. There have been no subjects 
who developed pseudoprogression in ICPI re-
challenge therapy because ICPI rechallenge itself 
was not an established treatment. To our best 
knowledge, this is the first case report describing 
a pseudoprogression developed in successful re-
challenge of ICPI therapy for a recurrent NSCLC 
patient. Clinicopathological factors that predict 
the development of pseudoprogression, including 
clinical factors and laboratory findings (e.g., size 
of tumors, peripheral blood counts, circulating 
tumor DNA, cytokine levels) have been investigat-
ed [11, 14]. However, these potential biomarkers 
have been inconsistent, probably due to small 
sample sizes, different tumor types, and hetero-
geneous definitions of these atypical responses 
[14]. Investigating the presence and activity of 
immune cells in the tumor area at the time of 
tumor growth by tumor biopsy might help assess 
tumor immunity, nevertheless, this has not yet 
been proven as a validated biomarker [14]. Con-
sidering the frequency of pseudoprogression, it 
is not practical to perform a tumor biopsy when 
the tumor grows. Lee et al. [15] showed that cir-
culating tumor DNA decreased in the presence 
of pseudoprogression, but this method has not 
reached the level of clinical application. There-
fore, unfortunately, no reliable assessment has 
been reported to date to help clinicians decide 
between a potential pseudoprogression or a real 
progression [11, 14].
Although it remains unknown in which pa-
tients ICPI rechallenge might be effective, on the 
other hand, previous studies have suggested the 
predictive factors of the efficacy of the therapy [2–
7]. Some of them were as follows: 1) high tumor 
PD-L1 expression [5], 2) good response to the first 
ICPI therapy [2, 6, 7], 3) radiation therapy before 
ICPI rechallenge [4, 6], 4) short duration between 
the initial ICPI therapy and the rechallenge [3, 6], 
5) good response to prior chemotherapy [3], 
6) presence of immune-related adverse events 
in initial ICPI therapy [6], and 7) prior therapy 
including vascular endothelial growth factor in-
hibitor [3]. Some of the factors were relevant to 
our patient. Among them, ‘good response to the 
first ICPI therapy’ and ‘short duration between the 
initial ICPI and the rechallenge’ was apparently 
inconsistent. As for predictive factors of the effica-
cy of rechallenge therapy, there are contradictions 
and confusions like this. In a large study using 
national data base, Levra et al. [2] suggested that 
the outcome after retreatment with ICPI follow-
ing a first course of ICPI was significantly better 
in patients with a longer duration of initial ICPI 
treatment. Identification of which patients most 
benefit from rechallenge with ICPIs and which 
patients do not, will be one of the most important 
question to address in future studies.
We reported a pseudoprogression in success-
ful rechallenge ICPI therapy for a NSCLC patient. 
As shown in our case, pseudoprogression could be 
developed even in patients with ICPI rechallenge. 
When several therapies are exhausted, indications 
for ICPI rechallenge may be considered. The 
clinical experience in our patient might help in 
that time.
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Figure 2. The consecutive lines of treatment in a patient with progression-free survival indication
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